RESUMEN
Myopia is a major cause of visual impairment. Its prevalence is growing steadily, especially in East Asia. Despite the immense disease and economic burden, there are currently no Food and Drug Administration-approved drugs for myopia. This review aims to summarise pharmaceutical interventions of myopia at clinical and preclinical stages in the last decade and discuss challenges for preclinical myopia drugs to progress to clinical trials. Atropine and oral 7-methylxanthine are shown to reduce myopia progression in human studies. The former has been extensively studied and is arguably the most successful medication. However, it has side effects and trials on low-dose atropine are ongoing. Other pharmaceutical agents being investigated at a clinical trial level include ketorolac tromethamine, oral riboflavin and BHVI2 (an experimental drug). Since the pathophysiology of myopia is not fully elucidated, numerous drugs have been tested at the preclinical stage and can be broadly categorised based on the proposed mechanisms of myopisation, namely antimuscarinic, dopaminergic, anti-inflammatory and more. However, several agents were injected intravitreally or subconjunctivally, hindering their progress to human trials. Furthermore, with atropine being the most successful medication available, future preclinical interventions should be studied in combination with atropine to optimise the treatment of myopia.
Asunto(s)
Quimioterapia , Miopía/tratamiento farmacológico , Preparaciones Farmacéuticas , Administración Oral , Animales , Antiinflamatorios no Esteroideos/uso terapéutico , Atropina/uso terapéutico , Ensayos Clínicos como Asunto , Progresión de la Enfermedad , Evaluación Preclínica de Medicamentos , Humanos , Ketorolaco Trometamina/uso terapéutico , Midriáticos/uso terapéutico , Miopía/diagnóstico , Riboflavina/uso terapéutico , Complejo Vitamínico B/uso terapéutico , Xantinas/administración & dosificaciónRESUMEN
OBJECTIVES: This study was aimed to develop dual-purpose natamycin (NAT)-loaded niosomes in ketorolac tromethamine (KT) gels topical ocular drug delivery system to improve the clinical efficacy of natamycin through enhancing its penetration through corneal tissue and reducing inflammation associated with Fungal keratitis (FK). SIGNIFICANCE: Nanosized carrier systems, as niosomes would provide great potential for improving NAT ocular bioavailability.NAT niosomal dispersion formulae were prepared and then incorporated in 0.5%KT gels using different mucoadhesive viscosifying polymers. METHODS: Niosomes were prepared using the reverse-phase evaporation technique. In vitro experimental, and in vivo clinical evaluations for these formulations were done for assessment of their safety and efficacy for treatment of Candida Keratitis in Rabbits. In vitro release study was carried out by the dialysis method. In vivo and histopathological studies were performed on albino rabbits. RESULTS: NAT niosomes exhibited high entrapment efficiency percentage (E.E%) up to96.43% and particle size diameter ranging from 181.75 ± 0.64 to 498.95 ± 0.64 nm, with negatively charged zeta potential (ZP). NAT niosomal dispersion exhibited prolonged in vitro drug release (40.96-77.49% over 24h). NAT-loaded niosomes/0.5%KT gel formulae revealed retardation in vitro release, compared to marketed-product (NATACYN®) and NAT-loaded niosomes up to57.32% (F8). In vivo experimental studies showed the superiority for F8 in treatment of candida keratitis and better results on corneal infiltration and hypopyon level. These results were consistent with histopathological examination in comparison with F5 and combined marketed products (NATACYN® and Ketoroline®). CONCLUSIONS: This study showed that F8 has the best results from all pharmaceutical in vitro evaluations and a better cure percent in experimental application and enhancing the prolonged delivery of NAT and penetrating the cornea tissues.
Asunto(s)
Candida/efectos de los fármacos , Composición de Medicamentos/métodos , Queratitis/tratamiento farmacológico , Ketorolaco Trometamina/farmacología , Natamicina/farmacología , Administración Oftálmica , Animales , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Disponibilidad Biológica , Córnea/metabolismo , Inhibidores de la Ciclooxigenasa/farmacología , Inhibidores de la Ciclooxigenasa/uso terapéutico , Modelos Animales de Enfermedad , Combinación de Medicamentos , Evaluación Preclínica de Medicamentos , Liberación de Fármacos , Geles , Humanos , Queratitis/microbiología , Ketorolaco Trometamina/uso terapéutico , Liposomas , Masculino , Pruebas de Sensibilidad Microbiana , Nanopartículas/química , Natamicina/uso terapéutico , Tamaño de la Partícula , Permeabilidad , Polímeros/química , ConejosRESUMEN
Epidemiologic studies report improved breast cancer survival in women who receive ketorolac (Toradol) for postoperative pain relief compared with other analgesic agents. Ketorolac is a racemic drug. The S-enantiomer inhibits cyclooxygenases; R-ketorolac is a selective inhibitor of the small GTPases Ras-related C3 botulinum toxin substrate 1 (Rac1) and cell division control protein 42 (Cdc42), which are signaling molecules up-regulated during breast cancer progression and metastasis. The goal of this study was to determine whether R-ketorolac altered breast cancer development in the mouse mammary tumor virus-polyoma middle T-antigen model. Mice were administered ketorolac orally at 1 mg/kg twice daily to approximate the typical human dose. Mammary glands were analyzed for tumor number and immunohistochemical markers of proliferation and differentiation. R-ketorolac treatment significantly reduced mammary epithelial proliferation, based on Ki67 staining, and suppressed tumor development. Proliferative mammary epithelium from R-ketorolac-treated mice displayed greater differentiation, based on significantly higher total E-cadherin and decreased keratin 5 staining than epithelium of placebo-treated mice. No differences were detected in estrogen receptor, progesterone receptor, ß-catenin, or vimentin expression between placebo and R-ketorolac treatment groups. These findings indicate that R-ketorolac treatment slows tumor progression in an aggressive model of breast cancer. R-ketorolac may thus represent a novel therapeutic approach for breast cancer prevention or treatment based on its pharmacologic activity as a Rac1 and Cdc42 inhibitor.
Asunto(s)
Antineoplásicos/uso terapéutico , Ketorolaco Trometamina/uso terapéutico , Neoplasias Mamarias Animales/prevención & control , Administración Oral , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/farmacología , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Progresión de la Enfermedad , Esquema de Medicación , Evaluación Preclínica de Medicamentos/métodos , Células Epiteliales/efectos de los fármacos , Células Epiteliales/patología , Femenino , Ketorolaco Trometamina/administración & dosificación , Ketorolaco Trometamina/farmacología , Neoplasias Mamarias Animales/patología , Virus del Tumor Mamario del Ratón , Ratones Transgénicos , PoliomavirusRESUMEN
Films based on methylcellulose (MC) and pectin (PEC) of different ratios were prepared. MC/PEC (90:10) (MP10) gave the best results in terms of mechanical properties. Sodium montmorillonite (MMT) (1, 3 and 5 wt%) was incorporated in the MP10 matrix. The resulting films were characterized by X-ray diffraction and transmission electron microscopy, and it was found that nanocomposites were intercalated in nature. Mechanical studies established that addition of 3 wt% MMT gave best results in terms of mechanical properties. However, thermo-gravimetric and dynamic mechanical analysis proved that decomposition and glass transition temperature increased with increasing MMT concentration from 1 to 5 wt%. It was also observed that moisture absorption and water vapor permeability studies gave best result in the case of 3 wt% MMT. Optical clarity of the nanocomposite films was not much affected with loading of MMT. In vitro drug release studies showed that MC/PEC/MMT based films can be used for controlled transdermal drug delivery applications.
Asunto(s)
Bentonita/química , Portadores de Fármacos/química , Metilcelulosa/química , Nanocompuestos/química , Pectinas/química , Liberación de Fármacos , Humanos , Ketorolaco Trometamina/química , Fenómenos Mecánicos , Transición de Fase , Embalaje de Productos , Piel , Solubilidad , Solventes/química , Volatilización , Agua/químicaRESUMEN
BACKGROUND: Chronic pain or discomfort after hernia surgery is nowadays a more challenging concern than recurrence. This study aimed to evaluate the long-term impact of local anaesthetic repair (LA) on pain, discomfort, paraesthesia and functional outcome after Lichtenstein hernia repair as compared to locoregional (LRA) and general anaesthesia (GA). METHODS: patients with primary or recurrent inguinal hernia underwent Lichtenstein repair with a polypropylene mesh. All patients with a follow-up of at least three years were sent a detailed questionnaire and offered an outpatient visit. Kaplan-Meier estimates and Cox proportional hazard regressions were used to analyse the relationship between time to event variables and explanatory variables including anaesthesia type. RESULTS: Between 1994 and 2006, in two cohorts, 330 patients answered the questionnaire: 100 under GA, 35 under LRA, and 195 under LA. This represented a response rate of 95, 94, and 98% respectively. Compared to GA and LRA, LA resulted in less long term pain, discomfort and paraesthesia. Moreover, resumption of social and professional activities was faster after LA. Recurrence rates were 1, 0, and 0.5% respectively. CONCLUSIONS: After Lichtenstein inguinal hernia repair, LA results in beneficial effects beyond the immediate postoperative period.
Asunto(s)
Anestesia General , Anestesia Local , Hernia Inguinal/cirugía , Herniorrafia/métodos , Dolor Postoperatorio/prevención & control , Adulto , Anciano , Anestésicos Locales/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Bupivacaína/administración & dosificación , Femenino , Estudios de Seguimiento , Herniorrafia/efectos adversos , Humanos , Ketorolaco Trometamina/administración & dosificación , Lidocaína/administración & dosificación , Masculino , Persona de Mediana Edad , Dolor Postoperatorio/diagnóstico , Dolor Postoperatorio/etiología , Recurrencia , Encuestas y Cuestionarios , Resultado del TratamientoRESUMEN
ATP is an endothelium-dependent vasodilator, and findings regarding the underlying signaling mechanisms are equivocal. We sought to determine the independent and interactive roles of nitric oxide (NO) and vasodilating prostaglandins (PGs) in ATP-mediated vasodilation in young, healthy humans and determine whether any potential role was dependent on ATP dose or the timing of inhibition. In protocol 1 (n = 18), a dose-response curve to intrabrachial infusion of ATP was performed before and after both single and combined inhibition of NO synthase [N(G)-monomethyl-L-arginine (L-NMMA)] and cyclooxygenase (ketorolac). Forearm blood flow (FBF) was measured via venous occlusion plethysmography and forearm vascular conductance (FVC) was calculated. In this protocol, neither individual nor combined NO/PG inhibition had any effect on the vasodilatory response (P = 0.22-0.99). In protocol 2 (n = 16), we determined whether any possible contribution of both NO and PGs to ATP vasodilation was greater at low vs. high doses of ATP and whether inhibition during steady-state infusion of the respective dose of ATP impacted the dilation. FBF in this protocol was measured via Doppler ultrasound. In protocol 2, infusion of low (n = 8)- and high-dose (n = 8) ATP for 5 min evoked a significant increase in FVC above baseline (low = 198 ± 24%; high = 706 ± 79%). Infusion of L-NMMA and ketorolac together reduced steady-state FVC during both low- and high-dose ATP (P < 0.05), and in a subsequent trial with continuous NO/PG blockade, the vasodilator response from baseline to 5 min of steady-state infusion was similarly reduced for both low (ΔFVC = -31 ± 11%)- and high-dose ATP (ΔFVC -25 ± 11%; P = 0.70 low vs. high dose). Collectively, our findings indicate a potential modest role for NO and PGs in the vasodilatory response to exogenous ATP in the human forearm that does not appear to be dose or timing dependent; however, this is dependent on the method for assessing forearm vascular responses. Importantly, the majority of ATP-mediated vasodilation is independent of these putative endothelium-dependent pathways in humans.
Asunto(s)
Adenosina Trifosfato/fisiología , Óxido Nítrico/fisiología , Prostaglandinas/fisiología , Vasodilatación/fisiología , Absorciometría de Fotón , Adenosina Trifosfato/farmacología , Adulto , Composición Corporal , Arteria Braquial/efectos de los fármacos , Inhibidores de la Ciclooxigenasa/farmacología , Interpretación Estadística de Datos , Relación Dosis-Respuesta a Droga , Endotelio Vascular/fisiología , Inhibidores Enzimáticos/farmacología , Femenino , Antebrazo/irrigación sanguínea , Humanos , Ketorolaco Trometamina/farmacología , Masculino , Óxido Nítrico Sintasa de Tipo I/antagonistas & inhibidores , Flujo Sanguíneo Regional/efectos de los fármacos , Flujo Sanguíneo Regional/fisiología , Resistencia Vascular/efectos de los fármacos , Vasodilatación/efectos de los fármacos , Adulto Joven , omega-N-Metilarginina/farmacologíaRESUMEN
Ketorolac tromethamine is a potent analgesic and moderately effective anti-inflammatory drug approved for treatment of moderately severe acute pain as an intravenous/intramuscular injectable solution and an oral tablet. ROXRO PHARMA, Inc has developed an intranasal formulation, SPRIX, that delivers the drug with a similar pharmacokinetic profile to that obtained with intramuscular administration. Local tolerance and systemic toxicology studies were performed in rats and rabbits and showed that intranasal administration of SPRIX exhibits toxicity similar to that of other routes of administration and does not result in any adverse effects on the nasal passage and upper and lower respiratory system.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/toxicidad , Ketorolaco Trometamina/administración & dosificación , Ketorolaco Trometamina/toxicidad , Administración Intranasal , Animales , Antiinflamatorios no Esteroideos/sangre , Antiinflamatorios no Esteroideos/farmacocinética , Química Farmacéutica , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Tracto Gastrointestinal/efectos de los fármacos , Tracto Gastrointestinal/patología , Ketorolaco Trometamina/sangre , Ketorolaco Trometamina/farmacocinética , Masculino , Nariz/efectos de los fármacos , Nariz/patología , Conejos , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Pruebas de ToxicidadRESUMEN
OBJECTIVES: The objective of this study was to improve systemic delivery of the highly analgesic ketorolac trometamol (ketorolac tromethamine) via the transdermal route, through cost-effective topical formulations, to avoid most of the problems associated with ketorolac trometamol therapy. METHODS: In-vitro release behaviour of the drug from different microemulsion and emulgel formulations was evaluated. E2 emulgel (based on isopropyl myristate as penetration enhancer) and E7 emulgel (based on Brij 92 as penetration enhancer) were evaluated for their physical properties, rat skin permeation, in-vivo analgesic effect (hot-plate test and the paw pressure test), acute and chronic anti-inflammatory activity and gastric safety. KEY FINDINGS: Isopropyl myristate and the synergistic effect of the two known penetration enhancers (propylene glycol and Brij 92) significantly modulated drug permeation and may be a promising approach for the transdermal delivery of ketorolac trometamol and other drugs. Selected in-vivo tested formulae (E2 and E7) caused significantly less ulcer score and less gastric erosion compared with oral ketorolac trometamol. E7 showed significantly higher analgesic and anti-inflammatory activity compared with E2 with no significant difference compared with oral ketorolac trometamol. CONCLUSIONS: The developed ketorolac trometamol E7 emulgel appeared promising for dermal and transdermal delivery of ketorolac trometamol, which would circumvent most of the problems associated with drug therapy.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Excipientes/química , Ketorolaco Trometamina/administración & dosificación , Absorción Cutánea , Administración Cutánea , Animales , Antiinflamatorios no Esteroideos/farmacocinética , Antiinflamatorios no Esteroideos/toxicidad , Modelos Animales de Enfermedad , Emulsiones , Geles , Inflamación/tratamiento farmacológico , Inflamación/fisiopatología , Ketorolaco Trometamina/farmacocinética , Ketorolaco Trometamina/toxicidad , Masculino , Miristatos/química , Aceites de Plantas/química , Polietilenglicoles/química , Propilenglicol/química , Ratas , Úlcera Gástrica/inducido químicamenteAsunto(s)
Terapia por Estimulación Eléctrica , Terapia Electroconvulsiva/efectos adversos , Manejo del Dolor , Dolor/etiología , Anciano , Anestesia , Antiinflamatorios no Esteroideos/uso terapéutico , Femenino , Humanos , Ketorolaco Trometamina/uso terapéutico , Masculino , Persona de Mediana Edad , Enfermedades Musculares/etiología , Enfermedades Musculares/terapiaRESUMEN
The present study was aimed at developing safe and effective bioadhesive gelling systems of ketorolac tromethamine, a potent non-narcotic analgesic with moderate anti-inflammatory activity for nasal systemic delivery. Chitosan and pectin based gelling systems were prepared with variables like polymer concentration and type. These systems were characterized in terms of their physical properties, in vitro bioadhesion, in vitro drug release and long-term stability. The anti-inflammatory activity and mucosal irritancy of selected gels were also evaluated in rats and these results were compared with per oral, intraperitoneal and nasal solution administration of ketorolac tromethamine. All the prepared formulations gelled immediately at the nasal mucosal pH and showed longer contact time. Addition of hydroxypropyl methylcellulose (HPMC) in both chitosan and pectin based gelling systems increased the viscosity and gel strength. All the formulated gels exhibited pseudoplastic rheology and diffusion-controlled drug release. The results from stability studies revealed that the prepared thermogels showed marginal decrease in viscosity but at the same time, no significant difference in drug content, and in vitro release characteristics were observed before and after accelerated studies. The developed gelling systems produced only mild to negligible irritant effect to nasal mucosae as compared to control group.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Ketorolaco Trometamina/administración & dosificación , Adhesividad , Adhesivos , Administración Intranasal , Animales , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/farmacología , Química Farmacéutica , Química Física , Quitosano , Estabilidad de Medicamentos , Geles , Ketorolaco Trometamina/efectos adversos , Ketorolaco Trometamina/farmacología , Masculino , Mucosa Nasal/patología , Pectinas , Ratas , Ratas Wistar , Reología , SolubilidadRESUMEN
The objective of this work was to prepare and evaluate ketorolac tromethamine-loaded albumin microspheres using a factorial design. Albumin microspheres were prepared by emulsion cross-linking method. Selected formulations were characterized for their entrapment efficiency, particle size, surface morphology, and release behavior. Analysis of variance (ANOVA) for entrapment efficiency indicated that entrapment efficiency is best fitted to a response surface linear model. From the statistical analysis it was observed that as the drug:polymer (D:P) ratio and volume of glutaraldehyde increased, there was a significant increase in the encapsulation efficiency. Scanning electron microscopy of the microspheres revealed a spherical, nonporous and uniform appearance, with a smooth surface. Based on the entrapment efficiency and physical appearance, 9 formulations were selected for release study. The maximum particle size observed was below 40 microm. The release pattern was biphasic, characterized by an initial burst effect followed by a slow release. All selected microspheres, except those having less polymer proportion (D:P ratio is 1:1), exhibited a prolonged release for almost 24 hours. On comparing r (2) values for Higuchi and Peppas kinetic models, different batches of microspheres showed Fickian, non-Fickian, and diffusion kinetics. The release mechanism was regulated by D:P ratio and amount of cross-linking agent. From the experimental data obtained with respect to particle size and extent of drug release, it could be concluded that the prepared microspheres are useful for once-a-day intramuscular administration of ketorolac tromethamine.
Asunto(s)
Albúminas/química , Cápsulas/química , Portadores de Fármacos/química , Composición de Medicamentos/métodos , Inyecciones Intramusculares/métodos , Ketorolaco Trometamina/administración & dosificación , Ketorolaco Trometamina/química , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/química , Difusión , Evaluación Preclínica de Medicamentos , Emulsiones/química , Ensayo de Materiales , Microesferas , Tamaño de la Partícula , SolubilidadRESUMEN
PURPOSE: To evaluate the efficacy of pain relief by oral diazepam, acetaminophen, mefenamic acid, intramuscular ketorolac tromethamine, and peribulbar anaesthesia in panretinal photocoagulation (PRP). METHODS: A total of 220 patients with proliferative diabetic retinopathy requiring PRP treatment were enrolled in this study. Before laser treatment, the patients were allocated randomly to one of eight groups: group 1: diazepam (n=22), group 2: acetaminophen (n=21), group 3: mefenamic acid (n=21), group 4: diazepam and acetaminophen (n=22), group 5: diazepam and mefenamic acid (n=22), group 6: peribulbar anaesthesia with lidocaine (n=23), group 7: intramuscular injection of ketorolac tromethamine (n=22), group 8: placebo (n=67). Pain after the laser treatment was assessed by a verbal descriptive scale. Blood pressure and heart rate were measured before and after laser treatment. RESULTS: Patients receiving peribulbar anaesthesia had a significantly lower pain score than the control group (P<0.0001). Additionally, the peribulbar anaesthesia-treated group had the significantly least PRP-associated rise in either systolic (P=0.043) or diastolic blood pressure rates (P=0.030). There were no significant differences in pain score using other anesthetic agents when compared with the control group. There were no significant changes in heart rate after PRP treatment. CONCLUSION: Peribulbar anaesthesia is effective in reducing pain and blood pressure increase after PRP treatment. Oral diazepam, mefenamic acid, and acetaminophen (either alone or in combination with each other) are not effective in preventing PRP treatment-associated pain. Intramuscular injection of ketorolac tromethamine is also not effective in reducing PRP-associated pain.
Asunto(s)
Analgesia/métodos , Retinopatía Diabética/cirugía , Coagulación con Láser/efectos adversos , Dolor Postoperatorio/terapia , Acetaminofén , Anciano , Anestesia Local , Anestésicos Locales , Antiinflamatorios no Esteroideos , Presión Sanguínea , Diazepam , Femenino , Frecuencia Cardíaca , Humanos , Ketorolaco Trometamina , Lidocaína , Masculino , Ácido Mefenámico , Persona de Mediana Edad , Dimensión del Dolor , Estudios ProspectivosRESUMEN
BACKGROUND: Ketorolac is a potent nonsteroidal anti-inflammatory drug. Recently, a ketorolac prodrug, ketorolac propyl ester, was synthesized in our laboratory. The aim of the study was to evaluate the antinociceptive and anti-inflammatory effects of ketorolac propyl ester in five depot formulations. The vehicles used in these formulations were injectable vegetable oils, i.e., sesame oil, peanut oil, soybean oil, castor oil, and cottonseed oil. The traditional therapentic form of ketorolac tromethamine in saline was used as control. METHODS: Six studies were carried out to test the antinociceptive and anti-inflammatory effects of intramuscular ketorolac tromethamine (in saline) and its propyl ester (in five depot formulations) 240 micromol/kg on Sprague-Dawley rats treated with intraplantar carrageenin. RESULTS: Ketorolac tromethamine (in saline) produced an 8 h duration of action on both antinociception and anti-inflammation, whereas ketorolac propyl ester in five oily vehicles produced 54- to 78-h durations of actions in both antinociception and anti-inflammation. Ketorolac propyl ester in cottonseed oil produced a duration of action of 78h in both antinociception and anti-inflammation. CONCLUSIONS: All five depot formulations of ketorolac propyl ester produced longer durations of antinociceptive and anti-inflammatory effects.
Asunto(s)
Analgésicos/farmacología , Antiinflamatorios no Esteroideos/farmacología , Ketorolaco Trometamina/farmacología , Ketorolaco/farmacología , Profármacos/farmacología , Animales , Química Farmacéutica , Masculino , Aceites de Plantas/administración & dosificación , Ratas , Ratas Sprague-DawleyRESUMEN
Ketorolac tromethamine has to be given every 6 hr intramuscularly in patients for acute pain, so to avoid frequent dosing and patient inconvenience we found it to be a suitable candidate for parenteral controlled delivery by biodegradable microspheres for the present study. Ketorolac tromethamine-loaded microspheres were prepared by o/w emulsion solvent evaporation technique using different polymers: polycaprolactone, poly lactic-co-glycolic acid (PLGA 65/35), and poly lactic-co-glycolic acid (PLGA 85/15). To tailor the release profile of drug for several days, blends of PLGA 65/35 and PLGA 85/15 were prepared with polycaprolactone (PCL) in different ratios. The results revealed that microspheres made with 1:3 (PLGA65/35:PCL) blend released 97% of the drug in 5 days as compared 97% in 30 days in with pure PLGA65/35 microspheres. Microspheres made with 1:1 (PLGA65/35:PCL) and 3:1 (PLGA65/35:PCL released 98% of the drug in 30 days. In microspheres made with 1:3 (PLGA85/15:PCL), almost the entire drug was released in a week whereas in batches made with pure PLGA85/15 and 3:1 (PLGA 85/15:PCL) more than 80% of the drug was released in 60 days as compared with 96% in 60 days in 1:1 (PLGA85/15:PCL). Higher encapsulation efficiency was obtained with microspheres made with pure PLGA 65/35. These formulations were characterized for particle size analysis by Malvern mastersizer that revealed particle size in range of 12-15 micron and 12-22 micron for microspheres made with polymer blends of PLGA 65/35:PCL and PLGA85/15:PCL, respectively. In pure PLGA65/35 and PLGA85/15, particle size was 28 micron and 8 micron, respectively. Surface topography was studied by scanning electron microscopy that revealed a spherical shape of microspheres. From our study it as concluded that with careful selection of different polymers and their combinations, we can tailor the release of ketorolac tromethamine for long periods.
Asunto(s)
Preparaciones de Acción Retardada/farmacocinética , Ketorolaco Trometamina/farmacocinética , Microesferas , Tecnología Farmacéutica/métodos , Animales , Materiales Biocompatibles/administración & dosificación , Materiales Biocompatibles/química , Materiales Biocompatibles/farmacocinética , Biodegradación Ambiental , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/química , Evaluación de Medicamentos , Evaluación Preclínica de Medicamentos , Calor , Concentración de Iones de Hidrógeno , Inyecciones Subcutáneas , Ketorolaco Trometamina/administración & dosificación , Ketorolaco Trometamina/química , Ácido Láctico/química , Ratones , Microscopía Electrónica de Rastreo , Dimensión del Dolor/efectos de los fármacos , Tamaño de la Partícula , Poliésteres/química , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polímeros/química , Cola (estructura animal)/fisiopatología , Factores de TiempoRESUMEN
PURPOSE: To harvest microorganisms from the microkeratome after LASIK. To induce experimental infectious keratitis and investigate the use of routine postoperative medication. METHODS: During eight consecutive days, we cultured the plate of the microkeratome after routine LASIK. Dilutions of the most frequent microorganism was prepared according to the MacFarland scale. Ten microliters were injected into both corneas of eight guinea pigs. The right cornea was used as control and the left cornea was treated with 0.3% ciprofloxacin associated with dexamethasone and ketorolac tromethamine every 4 hours for 24 hours (group 2). The animals were sacrificed and the corneas were divided into two halves, which were sent to analyzed by the microbiology and histopathology laboratory. RESULTS: In the control group, Staphylococcus aureus could be retrieved from all corneas, while in group 2, only 50% showed positive cultures (p=0.0128). Histopathology concerning polymorphonuclear cells showed an intense degree of inflammation in group 1 (p=0.0203) and regarding monomorphonuclear cells, it was also more intense in group 1 (p=0.0051). CONCLUSION: This study suggests that the use of wide-spectrum antibiotic associated with anti-inflammatory eye drops has a significant effect on the reduction of a potential infectious and inflammatory process after refractive surgery.
Asunto(s)
Antiinfecciosos/uso terapéutico , Antiinflamatorios/uso terapéutico , Queratitis/tratamiento farmacológico , Queratomileusis por Láser In Situ , Complicaciones Posoperatorias/prevención & control , Infecciones Estafilocócicas/tratamiento farmacológico , Animales , Ciprofloxacina/uso terapéutico , Dexametasona/uso terapéutico , Modelos Animales de Enfermedad , Quimioterapia Combinada , Cobayas , Queratitis/microbiología , Ketorolaco Trometamina/uso terapéutico , Infecciones Estafilocócicas/complicaciones , Staphylococcus aureus/aislamiento & purificación , Staphylococcus epidermidis/aislamiento & purificaciónRESUMEN
Ketorolac tromethamine injected intramuscularly (IM) has been shown to be an effective analgesic in treating patients with acute musculoskeletal pain in the emergency department (ED). The authors compare the efficacy of a single dose of IM ketorolac to osteopathic manipulative treatment (OMT) as delivered in the ED for the management of acute neck pain. A randomized clinical trial was conducted in three EDs. A convenience sample of 58 patients with acute neck pain of less than three weeks' duration were enrolled. Subjective measures of pain intensity on an 11-point numerical rating scale were gathered from patients immediately before treatment and one hour afterward. Subjects received either OMT or 30 mg, IM ketorolac. Subjects' perceived pain relief was also recorded at one hour after treatment on a subjective 5-point pain relief scale. Twenty-nine patients received IM ketorolac, and 29 patients received OMT. Although both groups showed a significant reduction in pain intensity, 1.7+/-1.6 (P <.001 [95% CI, 1.1-2.3]) and 2.8+/-1.7 (P <.001 [95% CI, 2.1-3.4]), respectively, patients receiving OMT reported a significantly greater decrease in pain intensity (P=.02 [95% CI, 0.2-1.9]). When comparing pain relief at one hour posttreatment, there was no significant difference between the OMT and ketorolac study groups (P=.10). The authors found that, at one hour posttreatment, OMT is as efficacious as IM ketorolac in providing pain relief and significantly better in reducing pain intensity. The authors conclude that OMT is a reasonable alternative to parenteral nonsteroidal anti-inflammatory medication for patients with acute neck pain in the ED setting.
Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Ketorolaco Trometamina/uso terapéutico , Osteopatía , Dolor de Cuello/terapia , Enfermedad Aguda , Adulto , Antiinflamatorios no Esteroideos/administración & dosificación , Servicio de Urgencia en Hospital , Femenino , Humanos , Inyecciones Intramusculares , Ketorolaco Trometamina/administración & dosificación , MasculinoRESUMEN
Ketoprofen lysine salt(Artrosilene injectable solution) is a non-steroidal anti-inflammatory agent frequently administered by slow intravenous infusion with portable elastomeric infusion systems in association regimen with other analgesic drugs. The aim of this study was to investigate the physicochemical compatibility between ketoprofen lysine salt(Artrosilene injectable solution) and other injectable drugs frequently used in association, such as tramadol hydrochloride, keterolac tromethamine and morphine hydrochloride, into the Infusor LV5, Baxter elastomeric infusion system. Physicochemical properties of drug mixture, including colour, clarity, pH and drug content were observed or measured by a reversed-phase HPLC method with UV detection, before and after (up to 7 days) mixing at room temperature and under light protection. The results obtained demonstrated the physicochemical compatibility of ketoprofen lysine salt(Artrosilene injectable solution) with all drug formulations at every tested mixing ratios into Baxer Infusor LV5 infusion devices.
Asunto(s)
Antiinflamatorios no Esteroideos/química , Cetoprofeno/análogos & derivados , Lisina/análogos & derivados , Analgésicos Opioides/análisis , Analgésicos Opioides/química , Antiinflamatorios no Esteroideos/análisis , Fenómenos Químicos , Química Física , Cromatografía Líquida de Alta Presión , Color , Combinación de Medicamentos , Incompatibilidad de Medicamentos , Embalaje de Medicamentos , Elastómeros , Concentración de Iones de Hidrógeno , Bombas de Infusión , Cetoprofeno/análisis , Cetoprofeno/química , Ketorolaco Trometamina/análisis , Ketorolaco Trometamina/química , Lisina/análisis , Lisina/química , Morfina/análisis , Morfina/química , Soluciones Farmacéuticas , Tramadol/análisis , Tramadol/químicaRESUMEN
One of the prerequisites for a parenteral preparation is that the excipients incorporated are biocompatible and biodegradable. In the present study hydrophilic and hydrophobic excipients were investigated for developing an intramuscular sustained-release formulation of ketorolac. Kollidon 17 PF, Peceol (glyceryl monooleate), and castor oil were chosen as the potential release-retarding agents, each with a distinct mechanism of action. They were evaluated by in vitro drug-release profiles and in vivo pharmacodynamic and pharmacokinetic study in mice. Cumulative drug release was determined for standard and test formulations in modified Franz diffusion cell. Pharmacodynamic parameter, T = 70% response of peak analgesic response, was used to compare the performance of test formulations. Based on pharmacodynamic/pharmacokinetic correlation in the animal studies, Css(max) and Css(min) of 51.39 and 30.0 microg/mL, respectively, were determined and considered as performance markers for pharmacokinetic evaluation of test formulations. The study suggested that the sustained-release capability of glyceryl monooleate was maximum followed by that of castor oil and Kollidon 17 PF, when compared to conventional ketorolac tromethamine formulation. It was inferred that water soluble excipient, though, showed release retarding property in vitro but could not maintain it in the in vivo environment. Glyceryl monooloeate-based formulation produced the most favorable drug blood concentration vs. time profile.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Ketorolaco Trometamina/farmacocinética , Excipientes Farmacéuticos/farmacología , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/química , Aceite de Ricino/química , Aceite de Ricino/farmacología , Química Farmacéutica , Preparaciones de Acción Retardada , Excipientes/química , Excipientes/farmacología , Glicéridos/química , Glicéridos/farmacología , Inyecciones Intramusculares , Inyecciones Intraperitoneales , Ketorolaco Trometamina/administración & dosificación , Ketorolaco Trometamina/química , Masculino , Ratones , Dimensión del Dolor , Excipientes Farmacéuticos/química , Povidona/farmacología , Solubilidad , Factores de TiempoRESUMEN
PURPOSE: To investigate preoperative and postoperative prophylactic treatment with different pharmacological agents before flap cutting and exposure to a diffuse lamellar keratitis (DLK) causative agent. SETTING: Magill Research Center for Vision Correction, Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, USA. METHODS: The study comprised 48 eyes of 24 Dutch-belted rabbits. Three days before a corneal flap was cut and the corneal interface was exposed to Pseudomonas aeruginosa lipopolysaccharide endotoxin, a DLK causative agent, the eyes were randomly assigned to treatment with a mast-cell stabilizer, a nonsteroidal antiinflammatory drug (NSAID), or a corticosteroid or left without treatment as controls. The treatment was maintained throughout the 1-week follow-up. Slitlamp examinations and photographs were performed at 1, 3, 5, and 7 days; DLK was graded by a masked observer from 0 (no DLK) to IV. Corneal interface scrapings were performed in selected eyes on day 7. RESULTS: At the end of the follow-up, 36 eyes were available for evaluation. At 1 week, 100% of the control eyes and the eyes treated with the mast-cell stabilizer developed DLK; in the NSAID-treated and corticosteroid-treated eyes, the DLK rate was 86% and 70%, respectively. At 1 day, the severity of DLK was significantly lower in eyes treated with the mast-cell stabilizer (0.44) and at 7 days, it was significantly lower in corticosteroid-treated eyes (0.3) than in the control group (1.5 and 1.4, respectively) (P<.05, Wilcoxon test). Corneal interface scraping from an eye with grade III DLK showed numerous inflammatory cells. CONCLUSIONS: Preoperative and postoperative treatment with corticosteroids significantly reduced the severity of DLK compared to the untreated control eyes in this animal model. Treatment with a mast-cell stabilizer and an NSAID had less effect on the postoperative course of DLK.